MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
BCRX - Biocryst Pharmaceuticals Inc.
$9.14
-0.02(-0.16%)8:24:49 PM 1/26/2021
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug RAPIVAB was approved by FDA in Dec 2014. It has also been approved in Japan, Korea and China The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
Stock Chart

Summary:

  • RSI is at a high level of 72. A high level of RSI indicates the stock is overbought.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/25/2021BCRX
    BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo

    BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.

    01/22/2021BCRX
    Looking Into Biocryst Pharmaceuticals's Return On Capital Employed

    In Q3, Biocryst Pharmaceuticals (NASDAQ:BCRX) posted sales of $6.10 million. Earnings were up 11.31%, but Biocryst Pharmaceuticals still reported an overall loss of $42.86 million. In Q2, Biocryst Pharmaceuticals brought in $2.87 million in sales but lost $38.51 million in earnings.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally ...

    01/22/2021BCRX
    BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema

    ORLADEYO™ (berotralstat) 150 mg, for Japan ORLADEYO™ (berotralstat) 150 mg, for Japan RESEARCH TRIANGLE PARK, N.C., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO™ (berotralstat) 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. ORLADEYO is ...

    01/7/2021BCRX
    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees inducement options to purchase an aggregate of 240,500 shares of BioCryst common stock on December 31, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The option...

    01/6/2021BCRX
    BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m. ET. Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.About BioCryst Pharmaceuticals BioCryst Phar...

    12/23/2020BCRX
    Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More

    Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.

    12/23/2020BCRX
    BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall

    BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).

    12/23/2020BCRX
    2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started

    If you are looking for high-growth healthcare stocks that could go even higher, check out BioCryst Pharmaceuticals (NASDAQ: BCRX) and Cryoport (NASDAQ: CYRX). On Dec. 3, the U.S. Food and Drug Administration (FDA) approved the company's lead asset, Orladeyo (berotralstat), as the first oral, once-daily pill to prevent hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years or older. The market considers this to be a major win, since BioCryst's market capitalization has sw...